Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

Tommaso Stroffolini, Piero Luigi Almasio, Marcello Persico, Simona Bollani, Luisa Benvegnù, Giovangiuseppe Di Costanzo, Giuseppe Pastore, Alessio Aghemo, Gianfranca Stornaiuolo, Alessandra Mangia, Pietro Andreone, Maria Stanzione, Giuseppe Mazzella, Giorgio Saracco, Paolo Del Poggio, Savino Bruno

Research output: Contribution to journalArticle

Abstract

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis treated with IFN between 1992 and 1997 was analyzed. All subjects have been surveilled every 6 months by ultrasound. Independent predictors of HCC were assessed by Cox multiple regression analysis. RESULTS: Mean follow-up was 96.1 months. Anti-HBc testing was available in 693 cases and, among them, 303 patients (43.7%) were anti-HBc seropositive. Anti-HBc positive patients were more often men (67.0% vs 58.7%, P = 0.03), had lower transaminase levels (3.3 ± 2.0 vs 3.8 ± 2.5 u.l.n., P = 0.004), and had higher rate of alcohol intake (38.3% vs 22.5%, P <0.001) than anti-HBc negative patients. Overall, the incidence rates of HCC per 100 person-years were 1.84 (95% CI 1.34-2.47) in the anti-HBc positive patients and 1.86 (95% CI 1.41-2.42) in anti-HBc negative ones. By Cox multiple regression, there was no association of serum anti-HBc with HCC development (HR 1.03, 95% CI 0.69-1.52) or liver-related deaths incidence (HR 1.21; 95% CI 0.76-1.95). CONCLUSIONS: In comparison with anti-HBc negative subjects, serum anti-HBc positive patients with HCV-related/HBsAg negative cirrhosis treated with IFN monotherapy did not show a greater risk of HCC.

Original languageEnglish
Pages (from-to)1966-1972
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume103
Issue number8
DOIs
Publication statusPublished - Aug 2008

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis'. Together they form a unique fingerprint.

  • Cite this

    Stroffolini, T., Almasio, P. L., Persico, M., Bollani, S., Benvegnù, L., Di Costanzo, G., Pastore, G., Aghemo, A., Stornaiuolo, G., Mangia, A., Andreone, P., Stanzione, M., Mazzella, G., Saracco, G., Del Poggio, P., & Bruno, S. (2008). Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. American Journal of Gastroenterology, 103(8), 1966-1972. https://doi.org/10.1111/j.1572-0241.2008.01912.x